Research Article

Complement activation by carotenoid derived aldehydes in cultured human vein epithelial cells

  1. Pei-Lin Wu1,
  2. Guo-Hua Lin1,
  3. Xiao-Dong Kang1,
  4. Hong Yuan1,
  5. Yue-Liang Shen2,*

Article first published online: 13 MAY 2009

DOI: 10.1002/ptr.2814

Issue

Phytotherapy Research

Phytotherapy Research

Volume 23, Issue 12, pages 1696–1700, December 2009

Additional Information

How to Cite

Wu, P.-L., Lin, G.-H., Kang, X.-D., Yuan, H. and Shen, Y.-L. (2009), Complement activation by carotenoid derived aldehydes in cultured human vein epithelial cells. Phytotherapy Research, 23: 1696–1700. doi: 10.1002/ptr.2814

Author Information

  1. 1

    Department of Physiology, School of Medicine, Hangzhou Normal University, Hangzhou 310036, China

  2. 2

    Department of Physiology, School of Medicine, Zhejiang University, Hangzhou 310058, China

*Department of Physiology, School of Medicine, Zhejiang University, Hangzhou 310058, China

Publication History

  1. Issue published online: 25 NOV 2009
  2. Article first published online: 13 MAY 2009
  3. Manuscript Accepted: 11 FEB 2009
  4. Manuscript Revised: 27 JAN 2009
  5. Manuscript Received: 12 AUG 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (154K)

Keywords:

  • carotenoid;
  • complement activation;
  • coronary heart disease

Abstract

This study was designed to determine the complement activation effects of carotenoid-derived aldehydes (CDA) on cultured human umbilical vein endothelial cells (HUVEC). A dose-dependent complement activation upon incubation of HUVEC with CDA was observed. Interestingly, the data showed that the alternative pathway was not activated. In addition, upon CDA treatment a significant number of apoptotic cells was also observed. The results revealed that CDA could activate the complement by way of the classical pathway. The study suggests that high carotenoid supplementation for the treatment of coronary heart disease should be used cautiously. Copyright © 2009 John Wiley & Sons, Ltd.

Get PDF (154K)